It is demonstrated that the TUBB4B inhibitor, mebendazole, effectively suppresses the enhanced proliferation in lower‐expression PNLDC1 models, positioning it as a promising therapeutic agent.
Abstract
Colorectal cancer (CRC) remains a leading cause of cancer‐related mortality, highlighting the urgent need for novel therapeutic strategies. In this study, we find that PARN‐like Domain Containing protein‐1 (PNLDC1), an endoplasmic reticulum‐localized deadenylase, lower expresses in 91 clinical CRC tissues. Using both in vitro and in vivo models, we identify PNLDC1 as a key tumor suppressor by modulating cell cycle progression in CRC. RNA‐immunoprecipitation and sequencing analyses reveal that PNLDC1 binds cell cycle‐associated mRNAs, with TUBB4B emerging as a critical target. PNLDC1 downregulates TUBB4B mRNA, whose regulated degradation is essential for PNLDC1's tumor‐suppressive function. Restoration of TUBB4B expression counteracts PNLDC1‐mediated suppression of CRC cell proliferation, underscoring its pivotal role in CRC pathogenesis. Importantly, we demonstrate that the TUBB4B inhibitor, mebendazole, effectively suppresses the enhanced proliferation in lower‐expression PNLDC1 models, including cell, mouse xenografts, and patient‐derived tumor‐like cell clusters, positioning it as a promising therapeutic agent. These findings establish PNLDC1 as a valuable biomarker and therapeutic target, paving the way for developing novel CRC treatments.
ABSTRACT Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality, yet mechanisms sustaining malignant progression remain incompletely defined. Integrative analyses across multiple HCC cohorts identified TUBA1B as one of the most consistently upregulated tubulin isotypes whose high expression associates wi...
Feng Lin, Hechun Lin, Junming Yu et al.· Advancement of science· 0 citations
Although transfer RNA-derived fragments (tRFs) regulate oncogenesis, their specific functions in colorectal carcinoma (CRC) remain unclear. Using RNA sequencing, we identified a novel fragment, tRF-16-WSNKP9D, significantly upregulated in CRC tissues. Clinically, high tRF-16-WSNKP9D levels strongly correlated with poor...
Zhi-Zheng Xu, Jing Xu, Jing-Jing Wang et al.· Genomics· 0 citations
The FEN1/EIF4A3/MUC1-C axis is established as a novel mechanism driving LUAD progression by concurrently regulating intrinsic malignancy and extrinsic immune evasion, presenting FEN1 targeting as a promising dual-hit therapeutic strategy.
Min Wu, Ben-Meng Wu, Xue-Bing Yan et al.· Cell Death and Disease· 0 citations
A novel epigenetic pathway orchestrated by PRMT5 that converges on the functional modulation of CBX8 to synchronously governs CD8⁺ T cell exclusion and tumor stemness is unveiled, nominating PRMT5 inhibition as a compelling therapeutic strategy for combination immunotherapy in TNBC.
Cong-Cong Chen, Yu-Heng Zhang, Chang Liu et al.· Oncogene· 0 citations
It is demonstrated that the m5C methyltransferase NSUN6 is significantly upregulated in EC tissues, and its expression correlates with higher tumor grade and unfavorable prognosis, and a proof‐of‐concept inhibitor, AL398, is provided, laying the groundwork for the development of first‐in‐class RNA methylation‐targeted...
Xiang-Zhuan Zhao, Lin-Lin Yang, Huanxiang Chen et al.· Advancement of science· 0 citations
It is identified that PABPC4, a member of PABPs, is upregulated during colorectal cancer progression and associated with poor prognosis, and a previously undiscovered PABPC4‐SPP1 axis in macrophages is revealed, which induces tumor‐promoting macrophages and CD8+ T cell dysfunction, thereby facilitating tumor progressio...
Meng Wang, Fang Yang, Yuan Gao et al.· Advancement of science· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.